Neuroblastoma, a childhood cancer that develops from neural cells on the adrenal glands, accounts for 15% of childhood cancer deaths. Almost half of children with high-risk neuroblastoma harbor extra copies of the gene MYCN (MYCN amplified), the primary driver of neuroblastoma and its resistance to therapy. "Treating neuroblastoma by directly targeting MYCN has been challenging,"